文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

多黏菌素B血液灌流用于内毒素活性非极高水平的脓毒性休克患者:EUPHRATES试验的事后分析

Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial.
PubMed 文献 · Intensive Care Med · 2018-11-23
一句话结论EUPHRATES事后分析提示,对EAA 0.6–0.89的脓毒性休克患者,多黏菌素B血液灌流可能改善28天死亡率、MAP和免机械通气天数,但属探索性假设生成结果。

该研究为EUPHRATES试验的事后分析,纳入194例完成两次治疗、基线内毒素活性(EAA)在0.6–0.89之间的脓毒性休克患者,比较多黏菌素B血液灌流(PMX)与假治疗。28天死亡率PMX组26.1%(23/88)vs 假治疗组36.8%(39/106),校正APACHE II和基线MAP后OR 0.52(95%CI 0.27–0.99),P=0.047;未校正时P=0.11。PMX组28天生存时间更长(HR 0.56,95%CI 0.33–0.95,P=0.03),MAP中位变化8 mmHg vs 4 mmHg(P=0.04),免机械通气天数中位20天 vs 6天(P=0.004)。作者结论为假设生成性结果,提示EAA 0.6–0.89的脓毒性休克患者可能对PMX有可测量的反应。

要点

  • EAA 0.6–0.89且完成两次治疗的脓毒性休克患者中,PMX组28天死亡率26.1%(23/88)vs 假治疗组36.8%(39/106),校正后OR 0.52(95%CI 0.27–0.99),P=0.047;未校正P=0.11。
  • PMX组28天生存时间较假治疗组延长(HR 0.56,95%CI 0.33–0.95,P=0.03)。
  • PMX组MAP中位变化8 mmHg(IQR -0.5至19.5)vs 假治疗组4 mmHg(IQR -4.0至11),P=0.04;免机械通气天数中位20天(IQR 0.5–23.5)vs 6天(IQR 0–20),P=0.004。
  • 培养无细菌生长的亚组中,PMX组死亡率6/30(20%)vs 假治疗组13/31(41.9%),P=0.005。
  • 该分析为EUPHRATES试验的探索性事后分析,作者称其为假设生成性结果。

适用人群与场景

  • EUPHRATES试验中脓毒性休克且EAA≥0.60的患者,本事后分析限定EAA在0.6–0.89之间并完成两次治疗(PMX或假治疗)的194例患者。
  • 亚组分析包括按中心和感染类型划分的亚组,以及基线去甲肾上腺素剂量>0.1 mcg/kg/min的患者。

诊断标准与关键阈值

  • 脓毒性休克合并内毒素活性(EAA)≥0.60定义为内毒素血症;本分析纳入EAA 0.6–0.89的患者。
  • EAA≥0.9被描述为内毒素活性极高。

研究设计与关键结果

  • 研究类型:EUPHRATES试验的事后分析,纳入194例EAA 0.6–0.89且完成两次治疗(PMX或假治疗)的脓毒性休克患者,PMX组88例、假治疗组106例。
  • 主要终点:28天死亡率PMX组26.1%(23/88)vs 假治疗组36.8%(39/106),风险差10.7%,校正APACHE II评分和基线MAP后OR 0.52(95%CI 0.27–0.99),P=0.047;未校正基线变量时P=0.11。
  • 28天生存时间:PMX组较假治疗组延长,HR 0.56(95%CI 0.33–0.95),P=0.03。
  • MAP变化:PMX组中位8 mmHg(IQR -0.5至19.5)vs 假治疗组4 mmHg(IQR -4.0至11),P=0.04;免机械通气天数:PMX组中位20天(IQR 0.5–23.5)vs 假治疗组6天(IQR 0–20),P=0.004。
  • 其他终点(累积血管加压药指数、EAA降低中位数、免透析天数、住院时间)无显著差异。
  • 亚组:培养无细菌生长的患者中,PMX组死亡率6/30(20%)vs 假治疗组13/31(41.9%),P=0.005。
  • 总体EAA变化中位数为-12.9%(范围:升高49.2%至降低86.3%);EAA变化高于中位数的患者中,PMX组死亡率6/38(15.7%)vs 假治疗组15/49(30.6%),P=0.08。

证据类型、等级与局限

  • 证据类型:EUPHRATES试验的探索性事后分析(post hoc analysis)。
  • 作者结论:这些假设生成性结果提示,EAA≥0.6至0.89的脓毒性休克患者对PMX在平均动脉压、免机械通气天数和死亡率方面可能有可测量的反应。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 本分析针对EAA 0.6–0.89且完成两次PMX或假治疗的脓毒性休克患者,作者认为结果属假设生成性,提示该类患者可能有多黏菌素B血液灌流相关反应。
  • 原文未据此给出推荐。

指南或共识出处

  • EUPHRATES试验,ClinicalTrials.gov注册号NCT01046669,由Spectral Medical Incorporated资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: The EUPHRATES trial examined the impact of polymyxin B hemoperfusion (PMX) on mortality in patients with septic shock and endotoxemia, defined as EAA ≥ 0.60. No difference was found in 28-day all-cause mortality. However, the trial showed that in some patients with septic shock the burden of endotoxin activity was extreme (EAA ≥ 0.9). In a post hoc analysis, we evaluated the impact of PMX use in patients with septic shock and endotoxin activity measured between 0.6-0.89.

METHODS: Post-hoc analysis of the EUPHRATES trial for the 194 patients with EAA ≥ 0.6-0.89 who completed two treatments (PMX or sham). The primary end point was mortality at 28 days adjusted for APACHE II score and baseline mean arterial pressure (MAP). Additional end points included changes in MAP, cumulative vasopressor index (CVI), median EAA reduction, ventilator-free days (VFD), dialysis-free days (DFD) and hospital length of stay. Subpopulations analyzed were site and type of infection and those with norepinephrine dose > 0.1 mcg/kg/min at baseline.

RESULTS: At 28 days, 23 patients of 88 (26.1%) in the PMX group died versus 39 of 106 (36.8%) in the sham group [risk difference 10.7%, OR 0.52, 95% CI (0.27, 0.99), P = 0.047]. When unadjusted for baseline variables, P = 0.11. The 28-day survival time in the PMX group was longer than for the sham group [HR 0.56 (95% CI 0.33, 0.95) P = 0.03]. PMX treatment compared with sham showed greater change in MAP [median (IQR) 8 mmHg (- 0.5, 19.5) vs. 4 mmHg (- 4.0, 11) P = 0.04] and VFD [median (IQR) 20 days (0.5, 23.5) vs. 6 days (0, 20), P = 0.004]. There were no significant differences in other end points. There was a significant difference in mortality in PMX-treated patients with no bacterial growth on culture [PMX, 6/30 (20%) vs. sham, 13/31 (41.9%), P = 0.005]. The median EAA change in the population was - 12.9% (range: increase 49.2%-reduction 86.3%). The mortality in the above median EAA change group was PMX: 6/38 (15.7%) vs. sham 15/49 (30.6%), P = 0.08.

CONCLUSIONS: These hypothesis-generating results, based on an exploratory post hoc analysis of the EUPHRATES trial, suggest measurable responses in patients with septic shock and an EAA ≥ 0.6 to 0.89 on changes in mean arterial pressure, ventilator-free days and mortality.

TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT01046669. Funding Spectral Medical Incorporated.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Klein DJ, Foster D, Walker PM, et al. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 2018. PMID: 30470853. doi:10.1007/s00134-018-5463-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。